NDAINTRAVENOUSSOLUTION
Approved
Jan 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
CORPHEDRA (ephedrine sulfate) by Pfizer is α- and ß adrenergic receptors and indirectly causes the release of norepinephrine from sympathetic neurons. Approved for allergic rhinitis. First approved in 2017.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CORPHEDRA is an intravenous ephedrine sulfate solution approved by Pfizer in 2017 for allergic rhinitis. It works by activating α- and β-adrenergic receptors and indirectly releasing norepinephrine from sympathetic neurons, producing pressor effects through increases in arterial pressure, cardiac output, and peripheral resistance. This is a small-molecule sympathomimetic agent with systemic hemodynamic activity.
Peak
Product is at peak lifecycle stage with moderate competitive pressure (30/100), suggesting stable but not expanding commercial operations; team size likely modest relative to growth-stage products.
Mechanism of Action
α- and ß adrenergic receptors and indirectly causes the release of norepinephrine from sympathetic neurons. Pressor effects by direct alpha- and beta-adrenergic receptor activation are mediated by increases in arterial pressures, cardiac output, and peripheral resistance. Indirect adrenergic…
Indications (1)
Clinical Trials (1)
Bioequivalence Study of Desloratadine and Pseudoephedrine Sulfate Extended-release Tablets Under Fasting Conditions
Started Apr 2006
34 enrolled
Healthy
Career Relevance
Working on CORPHEDRA offers limited external career visibility (zero linked job postings) but provides deep expertise in IV sympathomimetics, cardiovascular pharmacology, and rare/niche indications. The product's safety complexity and abuse liability make it valuable for regulatory and safety professionals seeking specialized experience.
Worked on CORPHEDRA at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.